Connect with us

Biotech

How synthetic DNA is revolutionizing research in biotechnology

DNA has been manufactured by chemical synthesis. A particularly long and costly process, with an error rate that increases as the sequence lengthens. Researchers are looking to develop alternatives to synthesize DNA more easily, with more convincing results. “Crispr-Cas9” is a genome transformation technique that allows DNA modification by targeting a gene with unparalleled accuracy.

Published

on

How far can we go with DNA? The scientific community does not yet have the answer, as the potential of this molecule seems infinite. But to study the possibilities offered in this field, laboratories must still have enough material for researchers to continue their work.

However, for the past forty years, DNA has been manufactured by chemical synthesis. A particularly long and costly process, with an error rate that increases as the sequence lengthens.

Researchers try to find ways to synthesize DNA

In this context, researchers are looking to develop alternatives to synthesize DNA more easily, with more convincing results. Among the solutions considered, one that particularly appealed to the scientific community: enzymatic synthesis. This process, which is faster and more efficient, and for which it is no longer necessary to be a chemist, is now used for the production of medicines, perfumes, cosmetics and biofuels.

The synthetic DNA market is estimated at $1.5 billion, with a growth of 10% per year. The French start-up DNA Script is developing a printer based on genetically modified enzymes to generate a personalized DNA sequence in a few hours. To make synthetic DNA a lever for predictive medicine, but not only, the company raised €11 million in September 2017. And also, an additional €35 million in May.

This picture show a lot of money, symbolising the earning that can be achieved in this field.
To make synthetic DNA a lever for predictive medicine, but not only, the company raised €11 million in September 2017 (Source)

Giving a second wind to the writing of genetic codes

Founded in 2014 by Thomas Ybert, Sylvain Gariel and Xavier Godron, DNA Script has developed a printer capable of synthesizing high-quality DNA to foster innovation in science and technology. Through this technology, DNA Script intends to give a second wind to the writing of genetic codes.

SEE ALSO  3 tips to better engage remote employees

The new process developed by the company makes it possible to produce better quality and longer DNA molecules. This process is donde in a much shorter time frame than usual production methods. And provides an opportunity for researchers in molecular biology to accelerate their experiments to achieve faster results.

This picture show a girl looking through a microscope.
DNA Script is developing a DNA printer based on genetically modified enzymes to generate a personalized DNA sequence in a few hours. (Source)

DNA Script’ genome transformation technique

These advances should eventually make it possible to develop new therapeutic products, such as medicines or vaccines. But also to move towards more ecological production of chemicals or to propose a new way of storing data.

DNA Script’s printer could even take on a new dimension with “Crispr-Cas9”. A genome transformation technique that allows DNA modification by targeting a gene with unparalleled accuracy. To understand better, FrenchWeb went to meet Xavier Godron and Sylvain Gariel. Two of the three founders of the French start-up, in their laboratory at the Kremlin-Bicêtre, south of Paris.

__

(Featured Image by madartzgraphics)

First published in frenchweb, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. B2I assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. B2I is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Continue Reading

Most Popular